55 related articles for article (PubMed ID: 19494837)
1. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K
Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837
[TBL] [Abstract][Full Text] [Related]
2. Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study.
Fu T; Chen Y; Lou L; Li Z; Shi W; Zhang X; Yang J
Egypt Heart J; 2024 Feb; 76(1):14. PubMed ID: 38300373
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A; Zhou H; Yang J; Li M; Niu T
Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma.
Allegra A; Casciaro M; Barone P; Musolino C; Gangemi S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681577
[TBL] [Abstract][Full Text] [Related]
5. A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1.
Huang Z; Li R; Tang T; Ling D; Wang M; Xu D; Sun M; Zheng L; Zhu F; Min H; Boonhok R; Ding Y; Wen Y; Chen Y; Li X; Chen Y; Liu T; Han J; Miao J; Fang Q; Cao Y; Tang Y; Cui J; Xu W; Cui L; Zhu J; Wong G; Li J; Jiang L
Cell Discov; 2020 Dec; 6(1):93. PubMed ID: 33311461
[TBL] [Abstract][Full Text] [Related]
6. Pluripotent stem cell-based screening identifies CUDC-907 as an effective compound for restoring the in vitro phenotype of Nakajo-Nishimura syndrome.
Kase N; Terashima M; Ohta A; Niwa A; Honda-Ozaki F; Kawasaki Y; Nakahata T; Kanazawa N; Saito MK
Stem Cells Transl Med; 2021 Mar; 10(3):455-464. PubMed ID: 33280267
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma.
Zhang S; Gong Z; Oladimeji PO; Currier DG; Deng Q; Liu M; Chen T; Li Y
Exp Hematol Oncol; 2019; 8():30. PubMed ID: 31788346
[TBL] [Abstract][Full Text] [Related]
8. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.
Vallet S; Filzmoser JM; Pecherstorfer M; Podar K
Pharmaceutics; 2018 Oct; 10(4):. PubMed ID: 30355994
[TBL] [Abstract][Full Text] [Related]
9. AP-1 confers resistance to anti-cancer therapy by activating XIAP.
Wang Y; Wan GH; Wu YM; Wang HS; Wang HF; Zhang G; Lu LL; Li ZQ; Chan KY; Zhou Y; Cai SH; Qi YF; Du J
Oncotarget; 2018 Mar; 9(18):14124-14137. PubMed ID: 29581832
[TBL] [Abstract][Full Text] [Related]
10. pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma.
Householder KT; DiPerna DM; Chung EP; Luning AR; Nguyen DT; Stabenfeldt SE; Mehta S; Sirianni RW
Colloids Surf B Biointerfaces; 2018 Jun; 166():37-44. PubMed ID: 29533842
[TBL] [Abstract][Full Text] [Related]
11. Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.
De Beule N; Menu E; Bertrand MJM; Favreau M; De Bruyne E; Maes K; De Veirman K; Radwanska M; Samali A; Magez S; Vanderkerken K; De Trez C
Oncotarget; 2017 Aug; 8(32):52016-52025. PubMed ID: 28881710
[TBL] [Abstract][Full Text] [Related]
12. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Tandon N; Ramakrishnan V; Kumar SK
Clin Pharmacol; 2016; 8():35-44. PubMed ID: 27226735
[TBL] [Abstract][Full Text] [Related]
13. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
Heinicke U; Kupka J; Fichter I; Fulda S
Oncogene; 2016 Jul; 35(28):3729-41. PubMed ID: 26616861
[TBL] [Abstract][Full Text] [Related]
14. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
15. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
Heinicke U; Kupka J; Fulda S
Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
[TBL] [Abstract][Full Text] [Related]
16. Discovery of protein acetylation patterns by deconvolution of peptide isomer mass spectra.
Abshiru N; Caron-Lizotte O; Rajan RE; Jamai A; Pomies C; Verreault A; Thibault P
Nat Commun; 2015 Oct; 6():8648. PubMed ID: 26468920
[TBL] [Abstract][Full Text] [Related]
17. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
18. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
Maes K; De Smedt E; Lemaire M; De Raeve H; Menu E; Van Valckenborgh E; McClue S; Vanderkerken K; De Bruyne E
Oncotarget; 2014 May; 5(10):3115-29. PubMed ID: 24833108
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Maes K; Menu E; Van Valckenborgh E; Van Riet I; Vanderkerken K; De Bruyne E
Cancers (Basel); 2013 Apr; 5(2):430-61. PubMed ID: 24216985
[TBL] [Abstract][Full Text] [Related]
20. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.
Lemaire M; D'Huyvetter M; Lahoutte T; Van Valckenborgh E; Menu E; De Bruyne E; Kronenberger P; Wernery U; Muyldermans S; Devoogdt N; Vanderkerken K
Leukemia; 2014 Feb; 28(2):444-7. PubMed ID: 24166214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
